LETROZOLE ATTENUATES CARDIOMETABOLIC RISK IN PLASMODIUM BERGHEI-INFECTED MICE
Abdulkareem, A., Babamale, A., Jesutomisin, C., Oluwabunmi, B., Ibiwumi, D., Olatunji, L., Ugbomoiko, U. (2023). LETROZOLE ATTENUATES CARDIOMETABOLIC RISK IN PLASMODIUM BERGHEI-INFECTED MICE. EKB Journal Management System, 46(1), 565-578. doi: 10.21608/bfsa.2023.301256
Adam Olaitan Abdulkareem; Abdulkareem Olarewaju Babamale; Caleb Omisope Jesutomisin; Badmos-king A Oluwabunmi; Dare B Ibiwumi; Lawrence Aderemi Olatunji; Uade Samuel Ugbomoiko. "LETROZOLE ATTENUATES CARDIOMETABOLIC RISK IN PLASMODIUM BERGHEI-INFECTED MICE". EKB Journal Management System, 46, 1, 2023, 565-578. doi: 10.21608/bfsa.2023.301256
Abdulkareem, A., Babamale, A., Jesutomisin, C., Oluwabunmi, B., Ibiwumi, D., Olatunji, L., Ugbomoiko, U. (2023). 'LETROZOLE ATTENUATES CARDIOMETABOLIC RISK IN PLASMODIUM BERGHEI-INFECTED MICE', EKB Journal Management System, 46(1), pp. 565-578. doi: 10.21608/bfsa.2023.301256
Abdulkareem, A., Babamale, A., Jesutomisin, C., Oluwabunmi, B., Ibiwumi, D., Olatunji, L., Ugbomoiko, U. LETROZOLE ATTENUATES CARDIOMETABOLIC RISK IN PLASMODIUM BERGHEI-INFECTED MICE. EKB Journal Management System, 2023; 46(1): 565-578. doi: 10.21608/bfsa.2023.301256

LETROZOLE ATTENUATES CARDIOMETABOLIC RISK IN PLASMODIUM BERGHEI-INFECTED MICE

Bulletin of Pharmaceutical Sciences Assiut University
Volume 46, Issue 1, June 2023, Page 565-578  XML PDF (1.28 MB)
Document Type: Original Article
DOI: 10.21608/bfsa.2023.301256
View on SCiNiTO View on SCiNiTO
Authors
Adam Olaitan Abdulkareem email orcid 1; Abdulkareem Olarewaju Babamale2; Caleb Omisope Jesutomisin3; Badmos-king A Oluwabunmi4; Dare B Ibiwumi4; Lawrence Aderemi Olatunji5; Uade Samuel Ugbomoiko4
1Animal Physiology Unit, Department of Zoology, University of Ilorin, Ilorin, Nigeria/ Pharmacology Division, CSIR-Central Drug Research Institute, Lucknow, India/ HOPE Cardiometabolic Research Team, University of Ilorin, Ilorin, Nigeria
2Parasitology Unit, Department of Zoology, University of Ilorin, Ilorin, Nigeria/ Taiwan International Graduate Program in Molecular Medicine, National Yang-Ming Chiao Tung University and Academia Sinica, Taipei, Taiwan
3Animal Physiology Unit, Department of Zoology, University of Ilorin, Ilorin, Nigeria
4Parasitology Unit, Department of Zoology, University of Ilorin, Ilorin, Nigeria
5Cardiovascular Research Unit, Department of Physiology, College of Health Sciences, University of Ilorin, Ilorin, Nigeria/ HOPE Cardiometabolic Research Team, University of Ilorin, Ilorin, Nigeria
Abstract
Malaria is associated with cardiometabolic disorders, promoting the risk of cardiovascular disease (CVD). We recently demonstrated letrozole’s cardioprotective effects in fructose-exposed male rats. Hence, in this study, we investigated the effect of a low-dose letrozole against cardiometabolic risk in Plasmodium berghei-infected female mice. Twenty female mice were randomly grouped into four (n=5/group): uninfected, infected, letrozole (0.24 mg/kg, p.o/day, without infection), and infected + letrozole. Weekly percentage parasitaemia was recorded. At the end of the 21-day exposure, blood and liver were collected and processed for biochemical analyses. P. berghei infection decreased serum estradiol level after 21-day infection and increased serum and liver levels of malondialdehyde, very low-density lipoprotein cholesterol, triglycerides, and triglycerides/high-density lipoprotein cholesterol (TG/HDL-c) index. Similarly, P. berghei elevated serum uric acid and hepatic total cholesterol levels. Meanwhile, the administered dose of letrozole did not significantly affect serum estradiol but lowered lipid peroxidation, attenuated lipid alterations, and reduced serum uric acid level. We reveal that P. berghei-infection lowered serum estradiol and promoted cardiometabolic risk in female mice, while letrozole lowered parasitaemia and mitigated the associated cardiometabolic risk. Thus, this study is suggestive of letrozole’s potential as an adjuvant therapy for improved management of malaria-induced cardiometabolic complications. Further study is recommended to investigate the anti-malaria potency of letrozole, independent of gender.
Keywords
Letrozole; malaria; cardiovascular risk; cardiometabolic disorder; CVD
Statistics
Article View: 176
PDF Download: 171